news
Six COVID-19 boosters are safe and effective, shows Phase II study
Study finds six different COVID-19 vaccine boosters increase immunity and pose no safety concerns, although immune responses varied.
List view / Grid view
VLA2001
news
EMA initiates rolling review of Valneva’s COVID-19 vaccine (VLA2001)
The European Medicines Agency (EMA)'s human medicines agency (CHMP) begins a rolling review of Valneva's COVID-19 vaccine VLA2001 following positive preliminary results.
news
Inactivated COVID-19 vaccine candidate enters comparative immunogenicity trial
The Phase III trial aims to demonstrate that Valneva’s VLA2001 is more immunogenic than AstraZeneca's conditionally approved COVID-19 vaccine, Vaxzevria.
news
Valneva begins manufacturing its inactivated, adjuvanted COVID-19 vaccine
The company announced that the Phase I/II trial for VLA2001 is now fully enrolled and that it has begun manufacturing the vaccine candidate on an industrial scale.
news
Valneva may provide Europe with the only inactivated virus vaccine for COVID-19
The Europe Commission is currently in discussions to procure millions of doses of Valneva’s COVID-19 innactivated virus vaccine, VLA2001.
news
Phase I/II trial initiated to study VLA2001, potential COVID-19 vaccine
Valneva has initiated its Phase I/II trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
news
UK government inks deal for 60 million doses of Valneva COVID-19 vaccine
Valneva has agreed to supply the UK government with 60 million doses of its potential COVID-19 vaccine by the second half of 2021.
